Your browser doesn't support javascript.
loading
Y-Chromosome Gene, Uty, Protects Against Pulmonary Hypertension by Reducing Proinflammatory Chemokines.
Cunningham, Christine M; Li, Min; Ruffenach, Gregoire; Doshi, Mitali; Aryan, Laila; Hong, Jason; Park, John; Hrncir, Haley; Medzikovic, Lejla; Umar, Soban; Arnold, Arthur P; Eghbali, Mansoureh.
Afiliación
  • Cunningham CM; Division of Molecular Medicine, Department of Anesthesiology.
  • Li M; School of Medicine, Stanford University, Stanford, California.
  • Ruffenach G; VA Palo Alto Health Care System, Palo Alto, California; and.
  • Doshi M; Division of Molecular Medicine, Department of Anesthesiology.
  • Aryan L; Division of Molecular Medicine, Department of Anesthesiology.
  • Hong J; Division of Molecular Medicine, Department of Anesthesiology.
  • Park J; University of Massachusetts Medical School, Worcester, Massachusetts.
  • Hrncir H; Division of Molecular Medicine, Department of Anesthesiology.
  • Medzikovic L; Division of Molecular Medicine, Department of Anesthesiology.
  • Umar S; Division of Pulmonary and Critical Care Medicine, Department of Medicine, and.
  • Arnold AP; Division of Molecular Medicine, Department of Anesthesiology.
  • Eghbali M; Department of Integrative Biology & Physiology, University of California, Los Angeles, Los Angeles, California.
Am J Respir Crit Care Med ; 206(2): 186-196, 2022 07 15.
Article en En | MEDLINE | ID: mdl-35504005
Rationale: Idiopathic pulmonary arterial hypertension (PAH) is a terminal pulmonary vascular disease characterized by increased pressure, right ventricular failure, and death. PAH exhibits a striking sex bias and is up to four times more prevalent in females. Understanding the molecular basis behind sex differences could help uncover novel therapies. Objectives: We previously discovered that the Y chromosome is protective against hypoxia-induced experimental pulmonary hypertension (PH), which may contribute to sex differences in PAH. Here, we identify the gene responsible for Y-chromosome protection, investigate key downstream autosomal genes, and demonstrate a novel preclinical therapy. Methods: To test the effect of Y-chromosome genes on PH development, we knocked down each Y-chromosome gene expressed in the lung by means of intratracheal instillation of siRNA in gonadectomized male mice exposed to hypoxia and monitored changes in right ventricular and pulmonary artery hemodynamics. We compared the lung transcriptome of Uty knockdown mouse lungs to those of male and female PAH patient lungs to identify common downstream pathogenic chemokines and tested the effects of these chemokines on human pulmonary artery endothelial cells. We further inhibited the activity of these chemokines in two preclinical pulmonary hypertension models to test the therapeutic efficacy. Measurements and Main Results: Knockdown of the Y-chromosome gene Uty resulted in more severe PH measured by increased right ventricular pressure and decreased pulmonary artery acceleration time. RNA sequencing revealed an increase in proinflammatory chemokines Cxcl9 and Cxcl10 as a result of Uty knockdown. We found CXCL9 and CXCL10 significantly upregulated in human PAH lungs, with more robust upregulation in females with PAH. Treatment of human pulmonary artery endothelial cells with CXCL9 and CXCL10 triggered apoptosis. Inhibition of Cxcl9 and Cxcl10 expression in male Uty knockout mice and CXCL9 and CXCL10 activity in female rats significantly reduced PH severity. Conclusions:Uty is protective against PH. Reduction of Uty expression results in increased expression of proinflammatory chemokines Cxcl9 and Cxcl10, which trigger endothelial cell death and PH. Inhibition of CLXC9 and CXLC10 rescues PH development in multiple experimental models.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Proteínas Nucleares / Antígenos de Histocompatibilidad Menor / Quimiocinas / Hipertensión Pulmonar Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans / Male Idioma: En Revista: Am J Respir Crit Care Med Asunto de la revista: TERAPIA INTENSIVA Año: 2022 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Proteínas Nucleares / Antígenos de Histocompatibilidad Menor / Quimiocinas / Hipertensión Pulmonar Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans / Male Idioma: En Revista: Am J Respir Crit Care Med Asunto de la revista: TERAPIA INTENSIVA Año: 2022 Tipo del documento: Article